News | November 08, 2021
Divis Labs PAT at Rs 606.46 cr. in Q2FY22
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Lyka Labs has reported consolidated financial results for the period ended September 30, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Subscribe To Our Newsletter & Stay Updated
